title: Continuing follow-up of malignant hypertension.
abstract: The history of accelerated (malignant) hypertension is reviewed, and unsolved problems related to the disease are illustrated, including its relationship to malignant nephrosclerosis, as well as terminology, current frequency and treatment. Over the past 25 years, out of a series of 131 patients, 53 were classified as suffering from essential malignant hypertension, the only suitable model on which the effects of pharmacological treatment on the disease can correctly be evaluated. In 2000, there were 24 survivors in our series and the maximum follow-up was 290 months. Multiple daily B.P. self-measurements allowed us to establish that pharmacological treatment was only able to approximate, to a varying degree, the conventional threshold of 140/90. Yet, despite this incomplete control over blood pressure levels, renal function was maintained in those patients whose initial creatininemia levels had not been higher than 2 mg/L. The renal protection effect of treatment was preserved even in patients who relapsed intoaccelerated disease phase one or more times over the study period.
authors.affiliation: Postgraduate School of Nephrology, University of Florence, Italy. ptsc@unifi.it
authors.forename: Paolo Tommaso
authors.initials: PT
authors.lastname: Scarpelli
authors.forename: Marco
authors.initials: M
authors.lastname: Gallo
authors.forename: Francesco
authors.initials: F
authors.lastname: De Cesaris
authors.forename: Gianna
authors.initials: G
authors.lastname: Chiari
authors.forename: Gianluca
authors.initials: G
authors.lastname: Dedola
authors.forename: Stefania
authors.initials: S
authors.lastname: Cappeli
authors.forename: Aureliano
authors.initials: A
authors.lastname: Becucci
authors.forename: Paola
authors.initials: P
authors.lastname: Becherelli
authors.forename: Benedetta
authors.initials: B
authors.lastname: Tosi
authors.forename: Carla
authors.initials: C
authors.lastname: Fanetti
authors.forename: Roberto
authors.initials: R
authors.lastname: Fanelli
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001795:Blood Pressure Determination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006974:Hypertension, Malignant / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods*; D009400:Nephrosclerosis / Q000517:prevention & control*; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D016019:Survival Analysis
chemical_list: D000959:Antihypertensive Agents